Full-Time
Confirmed live in the last 24 hours
Designs precision biologics using in vivo methods
Senior, Expert
Boston, MA, USA
You match the following Manifold Bio's candidate preferences
Employers are more likely to interview you if you match these preferences:
Manifold Bio focuses on creating precision biologics for the pharmaceutical industry. Their main product is an in vivo drug design platform, which allows for drug testing within living organisms rather than in laboratory settings. This platform utilizes mCodes™ technology, a unique protein barcoding system that enables the simultaneous study of multiple proteins in one experiment. This is particularly beneficial for testing complex biologics, which are large molecule drugs derived from living organisms. Unlike other companies, Manifold Bio's approach to drug design is the first of its kind, emphasizing in vivo testing. The company's goal is to expand their platform and collaborate with other pharmaceutical companies to develop new therapeutics.
Company Size
11-50
Company Stage
Series A
Total Funding
$58.8M
Headquarters
Boston, Massachusetts
Founded
2020
Help us improve and share your feedback! Did you find this helpful?
Manifold Bio secues $15M in Series A funding.
PALO ALTO, Calif.--(BUSINESS WIRE)--Playground Global, an early-stage, deep-tech venture firm that invests in founders building category-defining businesses at the forefront of science and technology, today announced that Benjamin Kim PhD, has been promoted to Partner. Ben focuses on identifying founders and companies that are revolutionizing engineered biology, building the future of emerging modality therapeutics development, and unlocking AI and ML workflows to refactor drug development. Ben joined Playground as a Venture Fellow in 2019 while completing his PhD in bioengineering at Stanford University. He became a Venture Associate a year later, and by 2022, he had led investments in two breakthrough biotech companies and was promoted to Venture Principal. In the last year, Ben has supported investments in Insamo (Board Observer and Lead Investor), Infinimmune (Board Director and Lead Seed Investor), Atomic AI (Board Observer and Lead Series A investor) and Amber Bio (Board Observer and Co-Led Seed Investment Round). He has also worked with Outpace Bio and Manifold Bio, where he is a Board Observer
Manifold Bio, a Boston, MA-based protein therapeutics company, raised $40M in Series A funding. The round was led by Triatomic Capital with participation from Section 32, FPV Ventures, Horizons Ventures, Tencent, Playground Global, Fifty Years, and FAST. With this funding, Triatomic Capital founding partner Jeff Huber will join Manifold Bio’s board of directors. Huber was previously founder and CEO of Grail and co-founder of Google’s life sciences efforts
Manifold Bio, a next-generation protein therapeutics company pioneering an in vivo biologics design platform, today announced the close of a $40 million Series A financing round led by Triatomic Capital and joined by new investors Section 32, FPV Ventures, Horizons Ventures, and Tencent.
In the creation of a new drug, there comes a point where you have to finally put the molecule in a real creature — one at a time — and see if it actually does what you think it does. Manifold Bio’s molecular machinery could let a hundred molecules be tested simultaneously in a single living system, potentially upending the whole process. The drug discovery space has advanced a lot in the last few years, first with fast and cheap gene transcription, then with CRISPR, then with AI-powered proteomics. You don’t have to know what all of those do, however, to understand that in the end, no matter how much they accelerate fundamental research, in vivo testing remains a major bottleneck
Manifold Bio, a new startup founded by one of Boston’s most prolific biotech entrepreneurs, has raised $40 million to develop a technology that could make testing cancer drugs more efficient.
Allston, MA – According to filings with the U.S. Securities and Exchange Commission, Manifold Bio is raising $39,999,985.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Gleb Kuznetsov played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development. About Manifold Bio
Manifold Bio raises seed round to bring massively multiplexed measurement to drug discovery.